prednisone has been researched along with AIDS Seroconversion in 34 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "excellent tolerance and efficacy of combined zidovudine and plasmapheresis therapy in peripheral neurological HIV-related vasculitis." | 7.68 | Successful treatment of HIV-related vasculitis with peripheral neuropathy with short-term steroids followed by the association of zidovudine and plasmapheresis. ( Cohen, P; Gayraud, M; Gherardi, R; Guillevin, L; Jarrousse, B; Leon, A; Lhote, F, 1993) |
| "Four children with acquired immunodeficiency syndrome and aphthous oral ulcers with severe odynophagia were treated with a short oral course of prednisone." | 3.69 | Treatment of resistant oral aphthous ulcers in children with acquired immunodeficiency syndrome. ( Bernstein, LJ; de Asis, ML; Schliozberg, J, 1995) |
| "excellent tolerance and efficacy of combined zidovudine and plasmapheresis therapy in peripheral neurological HIV-related vasculitis." | 3.68 | Successful treatment of HIV-related vasculitis with peripheral neuropathy with short-term steroids followed by the association of zidovudine and plasmapheresis. ( Cohen, P; Gayraud, M; Gherardi, R; Guillevin, L; Jarrousse, B; Leon, A; Lhote, F, 1993) |
| "Burkitt's lymphoma is an aggressive B-cell lymphoma that occurs in children and adults and is largely curable with the use of intensive and toxic chemotherapy." | 2.78 | Low-intensity therapy in adults with Burkitt's lymphoma. ( Cole, D; Dunleavy, K; Grant, C; Jaffe, ES; Little, RF; Pittaluga, S; Shovlin, M; Staudt, LM; Steinberg, SM; Widemann, B; Wilson, WH, 2013) |
| "58% of the non-Hodgkin's lymphomas occurred in patients with marked immunodeficiency, 85% were high grade malignancies and 47% had primary extranodal disease." | 2.67 | [Malignant lymphoma associated with HIV infection]. ( Becker, K; Clemens, MR; Fischer, T; Helm, EB; Knauf, W; Mitrou, PS; Pohl, C; Schrappe-Bächer, M; Serke, M; Westerhausen, M, 1991) |
| "Subcutaneous Panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of childhood non-Hodgkin lymphoma." | 1.39 | Subcutaneous Panniculitis-like T-cell lymphoma in two pediatric patients: an HIV-positive adolescent and a 4-month-old infant. ( Acree, SC; Cassarino, DS; Church, JA; Gaynon, PS; Pattengale, PK; Tovar, JP; Wang, LL, 2013) |
| "In a random HIV-seropositive population, malignant lymphomas were diagnosed in 31 patients, of whom 24 (77%) had non-Hodgkin lymphoma (NHL) and 7 (23%) Hodgkin lymphoma (HL)." | 1.28 | Malignant lymphomas in HIV-seropositive patients. Frequency, features, and prognosis. Report on 31 cases. ( Cervos-Navarro, J; Dienemann, D; Jautzke, G; Langford, A; Pohle, HD; Ruf, B; Schürmann, D; Stein, H, 1991) |
| "We gave prednisone to six boys with hemophilia who were infected with HIV in order to study its effects on their clinical status, serum immunoglobulins, lymphocyte populations, and serum HIV antigen concentrations." | 1.28 | Effects of prednisone on human immunodeficiency virus infection. ( Bringelsen, KA; Normansell, DE; Saulsbury, FT, 1991) |
| "In one patient, acquired immunodeficiency syndrome (AIDS) developed 12 months after splenectomy, but none of the other patients have evidence of AIDS." | 1.27 | Splenectomy for immune thrombocytopenia related to human immunodeficiency virus. ( Ferguson, CM, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (17.65) | 18.7374 |
| 1990's | 16 (47.06) | 18.2507 |
| 2000's | 5 (14.71) | 29.6817 |
| 2010's | 7 (20.59) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Painschab, MS | 1 |
| Kasonkanji, E | 1 |
| Zuze, T | 1 |
| Kaimila, B | 1 |
| Tomoka, T | 1 |
| Nyasosela, R | 1 |
| Nyirenda, R | 1 |
| Dhungel, BM | 1 |
| Mulenga, M | 1 |
| Chikasema, M | 1 |
| Tewete, B | 1 |
| Mtangwanika, A | 1 |
| Chiyoyola, S | 1 |
| Mhango, W | 1 |
| Chimzimu, F | 1 |
| Kampani, C | 1 |
| Krysiak, R | 1 |
| Shea, TC | 1 |
| Montgomery, ND | 1 |
| Fedoriw, Y | 1 |
| Gopal, S | 1 |
| Messori, A | 1 |
| Fadda, V | 1 |
| Maratea, D | 1 |
| Trippoli, S | 1 |
| Dunleavy, K | 1 |
| Pittaluga, S | 1 |
| Shovlin, M | 1 |
| Steinberg, SM | 1 |
| Cole, D | 1 |
| Grant, C | 1 |
| Widemann, B | 1 |
| Staudt, LM | 1 |
| Jaffe, ES | 1 |
| Little, RF | 1 |
| Wilson, WH | 1 |
| Pereira, R | 1 |
| Carvalho, J | 1 |
| Patrício, C | 1 |
| Farinha, P | 1 |
| Manley, K | 1 |
| Dunning, J | 1 |
| Nelson, M | 1 |
| Bower, M | 1 |
| Acree, SC | 1 |
| Tovar, JP | 1 |
| Pattengale, PK | 1 |
| Wang, LL | 1 |
| Church, JA | 1 |
| Gaynon, PS | 1 |
| Cassarino, DS | 1 |
| Zhu, SH | 1 |
| Yu, YH | 1 |
| Zhang, Y | 1 |
| Sun, JJ | 1 |
| Han, DL | 1 |
| Li, J | 1 |
| Huang, Q | 1 |
| Chang, KL | 1 |
| Gaal, KK | 1 |
| Weiss, LM | 1 |
| Kaplan, LD | 1 |
| Lee, JY | 1 |
| Ambinder, RF | 1 |
| Sparano, JA | 1 |
| Cesarman, E | 1 |
| Chadburn, A | 1 |
| Levine, AM | 1 |
| Scadden, DT | 1 |
| Kishimoto, M | 1 |
| Mor, A | 1 |
| Abeles, AM | 1 |
| Solomon, G | 1 |
| Pillinger, MH | 1 |
| Lee, MJ | 1 |
| Omoti, AE | 1 |
| Omoti, CE | 1 |
| de Asis, ML | 1 |
| Bernstein, LJ | 1 |
| Schliozberg, J | 1 |
| Hagemeister, FB | 1 |
| Bielory, L | 1 |
| Sohn, T | 1 |
| Rescigno, R | 1 |
| Naum, SM | 1 |
| Molloy, PJ | 1 |
| Kania, RJ | 1 |
| McGarr, J | 1 |
| Van Thiel, DH | 1 |
| Sebastián, JJ | 1 |
| Fuentes, J | 1 |
| García, S | 1 |
| Uribarrena, R | 1 |
| Yus, C | 1 |
| Boldova, I | 1 |
| Zanussi, S | 1 |
| Simonelli, C | 1 |
| D'Andrea, M | 1 |
| Comar, M | 1 |
| Bidoli, E | 1 |
| Giacca, M | 1 |
| Tirelli, U | 1 |
| Vaccher, E | 1 |
| De Paoli, P | 1 |
| Cohen, P | 1 |
| Guillevin, L | 1 |
| Gayraud, M | 1 |
| Lhote, F | 1 |
| Jarrousse, B | 1 |
| Leon, A | 1 |
| Gherardi, R | 1 |
| Bhama, JK | 1 |
| Azad, NS | 1 |
| Fisher, WE | 1 |
| Newman, NJ | 1 |
| Lessell, S | 1 |
| Bomfim da Paz, R | 1 |
| Kölmel, HW | 1 |
| Schneider, AM | 1 |
| Straus, DJ | 1 |
| Schluger, AE | 1 |
| Lowenthal, DA | 1 |
| Koziner, B | 1 |
| Lee, BJ | 1 |
| Wong, G | 1 |
| Clarkson, BD | 1 |
| Wassermann, K | 1 |
| Pothoff, G | 1 |
| Heitz, W | 1 |
| Kirn, E | 1 |
| Krueger, GR | 1 |
| Diehl, V | 1 |
| Eckert, G | 1 |
| Hilger, HH | 1 |
| Schürmann, D | 1 |
| Dienemann, D | 1 |
| Jautzke, G | 1 |
| Cervos-Navarro, J | 1 |
| Langford, A | 1 |
| Stein, H | 1 |
| Pohle, HD | 1 |
| Ruf, B | 1 |
| Mitrou, PS | 1 |
| Serke, M | 1 |
| Pohl, C | 1 |
| Becker, K | 1 |
| Schrappe-Bächer, M | 1 |
| Knauf, W | 1 |
| Westerhausen, M | 1 |
| Clemens, MR | 1 |
| Helm, EB | 1 |
| Fischer, T | 1 |
| Saulsbury, FT | 1 |
| Bringelsen, KA | 1 |
| Normansell, DE | 1 |
| Simpson, DM | 1 |
| Bender, AN | 1 |
| Farraye, J | 1 |
| Mendelson, SG | 1 |
| Wolfe, DE | 1 |
| Koury, MJ | 1 |
| Larach, JC | 1 |
| Leslie, WT | 1 |
| Frederick, WR | 1 |
| Callender, CO | 1 |
| Saxinger, CW | 1 |
| Flores, JC | 1 |
| Alexander, SS | 1 |
| Barnes, SE | 1 |
| Flagg, R | 1 |
| Walters, CS | 1 |
| Dunston, GM | 1 |
| Greaves, WL | 1 |
| Koop, HO | 1 |
| Holodniy, M | 1 |
| List, AF | 1 |
| Ferguson, CM | 1 |
| Radolf, JD | 1 |
| Kaplan, RP | 1 |
| Keyserlingk, H | 1 |
| Ludwig, WD | 1 |
| Seibt, H | 1 |
| Rühl, H | 1 |
| Höffken, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas[NCT00006436] | Phase 2 | 68 participants (Actual) | Interventional | 2001-01-29 | Active, not recruiting | ||
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Adults and Children With Previously Untreated Patients With Aggressive Non-Hodgkin's Lymphoma[NCT00001337] | Phase 2 | 348 participants (Actual) | Interventional | 1993-05-08 | Active, not recruiting | ||
| LINFOTARGAM: First-line Treatment With Dose-dense Chemotherapy Plus Rituximab (R-CHOP/14) and Highly Active Antiretroviral Therapy (HAART) in Patients With Diffuse Large B Cell Lymphoma (DLBCL) and Infection With the Human Immunodeficiency Virus (HIV)[NCT00466258] | Phase 4 | 50 participants (Anticipated) | Interventional | 2006-10-31 | Completed | ||
| Randomized Trial of CHOP Chemotherapy With or Without Rituximab (Chimeric Anti-CD20 Antibody) for HIV-Associated Non-Hodgkin's Lymphoma[NCT00003595] | Phase 3 | 120 participants (Actual) | Interventional | 1999-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival is time from treatment start date until date of death or date last known alive. (NCT00006436)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 83.7 |
"Complete response (CR) was assessed by the Cheson response criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes > 1.5 cm before therapy).~Complete response unconfirmed (CRu) is when a residual lymph node mass > 1.5 cm in greatest transverse diameter that has regressed by > 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. In organs involved by disease, any residual lesions that have decreased by > 75% in sum of the products of the greatest diameters or are < 1 cm, are consistent with scar, and stable over the last two treatments will be considered to fulfill criteria for CR." (NCT00006436)
Timeframe: The participants were followed for duration of complete response or complete response unconfirmed for a median of 15.4 years.
| Intervention | years (Median) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 13.9 |
Overall survival is time from treatment start date until date of death or date last known alive. (NCT00006436)
Timeframe: The participants were followed for survival for a median of 15.4 years.
| Intervention | years (Median) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 14.2 |
PFS is the time interval from study entry to documented evidence of disease progression or death due to any cause. Progression is defined according to the Cheson response criteria. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s). Confidence intervals were made, and a Kaplan-Meier curve of progression free survival was constructed. (NCT00006436)
Timeframe: The participants were followed for a median of 15.4 years.
| Intervention | years (Median) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 13.8 |
Toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). Febrile neutropenia is defined as a life-threatening complication requiring hospitalization and urgent broad-spectrum antibiotics. (NCT00006436)
Timeframe: Date treatment consent signed to date off study, approximately 209 months and 17 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 18 |
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Toxicity Criteria (CTC v2.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00006436)
Timeframe: Date treatment consent signed to date off study, approximately 209 months and 17 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 66 |
Complete response was assessed by the Cheson Response Criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes > 1.5 cm before therapy). (NCT00006436)
Timeframe: The participants were followed for an average of 6 months to determine response to therapy.
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 95 |
"Complete response (CR) was assessed by the Cheson response criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes > 1.5 cm before therapy).~Complete response unconfirmed (CRu) is when a residual lymph node mass > 1.5 cm in greatest transverse diameter that has regressed by > 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. In organs involved by disease, any residual lesions that have decreased by > 75% in sum of the products of the greatest diameters or are < 1 cm, are consistent with scar, and stable over the last two treatments will be considered to fulfill criteria for CR." (NCT00006436)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 82.5 |
PFS is the time interval from start of treatment to documented evidence of disease progression. Progression is defined according to the Cheson response criteria. Disease progression as indicated by imaging scans at one year following therapy. Disease progression is defined as increase of 25% or more in the sum of the products of the longest perpendicular diameters of all measured lesions compared to the smallest previous measurements, or the appearance of any new lesion(s). (NCT00006436)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 79.1 |
Participants with human immunodeficiency virus (HIV) who undergo chemotherapy may have a delay in the recovery of their normal CD4+ T-cells. This delay could result in an increased risk of infection. Recovery of CD4 cells counts is the time from end of therapy until the time that the CD4 counts first reached above 200 cells/uL. (NCT00006436)
Timeframe: From the end of chemotherapy every 3 months for the first 2 years
| Intervention | months (Median) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 2.5 |
The HIV viral load is a measure of actively replicating virus in the blood. If no anti-retroviral therapy is given, then reduction of this HIV viral load to manageable levels might risk infection. In our study, the recovery of HIV viral load was measured the time from the initiation of antiretroviral therapy until the viral load was undetectable or < 50 copies. (NCT00006436)
Timeframe: Either following or concurrently with combination chemo and biological therapy, approximately every 6 to 8 weeks after therapy was completed up to 16 months
| Intervention | months (Median) |
|---|---|
| Arm 1-Combination Chemo and Biological Therapy | 2 |
"1-year PFS is defined as participants who remain free of disease progression or death at one year from study entry. We compared the 1-year PFS of participants with negative results on interim positron emission tomography (PET) scans to those with positive results on interim PET scans.~PFS is defined as the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival." (NCT00006436)
Timeframe: 1 year
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Interim PET scan positive 1-year PFS | Interim PET scan negative 1 year PFS | |
| Arm 1-Combination Chemo and Biological Therapy | 61.5 | 89.3 |
PFS is the time interval from start of treatment to documented evidence of disease progression or death from any cause. Disease progression was assessed by positron emission tomography scans after 2 cycles (each cycle is 21 days + 7 days window) of therapy using the Deauville criteria. Deauville score of 4 or 5 is considered positive on interim PET scan while a Deauville score of 1 or 2 or 3 is considered negative. The outcomes of the Deauville score was compared to determine PET positive progression free survival. (NCT00006436)
Timeframe: Participants were followed for up to 10.2 years to determine their response on interim PET scans.
| Intervention | years (Median) | |
|---|---|---|
| Interim PET positive participants | Interim PET negative participants | |
| Arm 1-Combination Chemo and Biological Therapy | 10.2 | NA |
Cumulative number of cycles of hematologic toxicity. Hematologic (i.e., decrease in bone marrow and blood cells) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). (NCT00006436)
Timeframe: Up to 112 cycles (each cycle is 21 days + 7 days window)
| Intervention | cycles (Number) | |||||
|---|---|---|---|---|---|---|
| Febrile neutropenia | Neutropenia with a Nadir <500 cells/mm^3 | Neutropenia with a Nadir <100 cells/mm^3 | Thrombocytopenia with a Nadir <50,000 platelets/mm^3 | Thrombocytopenia with a Nadir <25,000 platelets/mm^3 | Anemia: hemoglobin <8 g/dL | |
| Arm 1-Combination Chemo and Biological Therapy | 25 | 112 | 77 | 40 | 6 | 36 |
Non-hematologic (i.e., not begin in bone marrow or blood) toxicity was assessed by the Common Toxicity Criteria (CTC v2.0). Grade 3 is severe. Grade 4 is life-threatening. Grade 5 is death related to adverse event. (NCT00006436)
Timeframe: Date treatment consent signed to date off study, approximately 209 months and 17 days.
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Serious infection | Neurologic event | Syncope | Confusion | Motor neuropathy | Vision disturbance | Hyperglycemia | Hypophosphatemia | Hypocalcemia | Hypokalemia | Hyponatremia | Dehydration | Mucositis/Stomatitis | Liver test abnormalities | Pancreatitis | Diarrhea | Constipation | Serious hemorrhage | Fatigue | Headache | Bone pain | Nausea | Anorexia | Hypoxia | Myelodysplastic syndrome | |
| Grade 3 | 17 | 0 | 1 | 1 | 0 | 1 | 4 | 2 | 2 | 1 | 1 | 1 | 6 | 6 | 1 | 2 | 1 | 5 | 2 | 5 | 1 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 4 | 0 |
| Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Overall response was determined by the Cheson Response Criteria. Participants with either a complete response (CR), complete response unconfirmed or partial response were considered responders. Less than a partial response was considered a non-response to therapy (i.e., Stable Disease and/or Progressive Disease). Complete response was defined as the disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size. Complete response unconfirmed is a residual lymph node mass > 1.5 cm in greatest transverse diameter that has regressed by > 75% in sum of the products of the greatest diameters, does not change over the last two treatments, and any biopsies obtained are negative will be considered to be in CR. Partial response is defined as a 50% or greater decrease in the sum of the products of the longest perpendicular diameters of all measured lesions lasting for a period of at least one month. (NCT00006436)
Timeframe: The participants were followed for an average of 6 months to determine response to therapy.
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Complete Response | Complete Response Unconfirmed | Partial Response | Non-Responder - Stable Disease | Non-Responder - Progressive Disease | |
| Arm 1-Combination Chemo and Biological Therapy | 53 | 10 | 1 | 1 | 1 |
1 review available for prednisone and AIDS Seroconversion
| Article | Year |
|---|---|
Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Castleman Disease; Cyclophosphamide; Do | 2013 |
6 trials available for prednisone and AIDS Seroconversion
| Article | Year |
|---|---|
Mature outcomes and prognostic indices in diffuse large B-cell lymphoma in Malawi: a prospective cohort.
Topics: Adult; Aged; Anti-Retroviral Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamid | 2019 |
Low-intensity therapy in adults with Burkitt's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Burkitt | 2013 |
Low-intensity therapy in adults with Burkitt's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Burkitt | 2013 |
Low-intensity therapy in adults with Burkitt's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Burkitt | 2013 |
Low-intensity therapy in adults with Burkitt's lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Burkitt | 2013 |
Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Castleman Disease; Cyclophosphamide; Do | 2013 |
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2005 |
Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Tran | 1990 |
[Malignant lymphoma associated with HIV infection].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 1991 |
28 other studies available for prednisone and AIDS Seroconversion
| Article | Year |
|---|---|
Treatments for non-Hodgkin lymphoma in HIV-positive patients: quantifying incremental benefit from 1993 to 2004 by metaregression.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Antiretrovir | 2013 |
Sustained complete remission of primary effusion lymphoma with adjunctive ganciclovir treatment in an HIV-positive patient.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cycl | 2014 |
HIV-associated gastric natural killer/T-cell lymphoma.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Atazanavir Sulfate; Cyclopho | 2012 |
Subcutaneous Panniculitis-like T-cell lymphoma in two pediatric patients: an HIV-positive adolescent and a 4-month-old infant.
Topics: Adolescent; Anti-Retroviral Agents; HIV Seropositivity; Humans; Immunocompromised Host; Immunosuppre | 2013 |
KSHV/HHV8-associated lymphoma simulating anaplastic large cell lymphoma.
Topics: AIDS-Related Opportunistic Infections; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derive | 2004 |
Syphilis mimicking Reiter's syndrome in an HIV-positive patient.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Reactive; Balanitis; False Positive Reactions; HIV Serop | 2006 |
Sudden onset of herpes zoster following chemotherapy for orbital lymphoma in a HIV positive patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Cyclop | 2007 |
Treatment of resistant oral aphthous ulcers in children with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adrenal Cortex Hormones; CD8-Positive T-Ly | 1995 |
Results of treatment of small non-cleaved cell lymphoma in patients without positive HIV serology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cause of Death; Cyclophospha | 1993 |
Bilateral red eyes in a patient infected with human immunodeficiency virus.
Topics: AIDS-Related Opportunistic Infections; Diagnosis, Differential; Eye Infections, Bacterial; HIV Serop | 1995 |
Use of thalidomide in treatment and maintenance of idiopathic esophageal ulcers in HIV+ individuals.
Topics: Acquired Immunodeficiency Syndrome; Adult; Esophageal Diseases; Female; HIV Seropositivity; HIV-1; H | 1995 |
[Primary gastric lymphoma in an HIV positive patient].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Gastroscopy; H | 1995 |
The effects of antineoplastic chemotherapy on HIV disease.
Topics: Antineoplastic Agents; CD4 Lymphocyte Count; CD8 Antigens; Clinical Trials, Phase III as Topic; Cycl | 1996 |
Successful treatment of HIV-related vasculitis with peripheral neuropathy with short-term steroids followed by the association of zidovudine and plasmapheresis.
Topics: Adult; AIDS-Related Opportunistic Infections; Combined Modality Therapy; HIV Seropositivity; Humans; | 1993 |
Primary anorectal lymphoma presenting as a perianal abscess in an HIV-positive male.
Topics: Abscess; Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Diseases; Biopsy, Needle; Cyclo | 2002 |
Bilateral optic neuropathies with remission in two HIV-positive men.
Topics: Adult; HIV Infections; HIV Seropositivity; Humans; Male; Optic Nerve Diseases; Prednisone; Prognosis | 1992 |
Meningitis with Burkitt like B-cell lymphoma in HIV infection.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Cyclophosphamide; Doxorubic | 1992 |
[Acute pneumocystosis during polychemotherapy following the MACOP-B protocol].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; Bronchi; Bronchoalveolar Lavage F | 1990 |
Malignant lymphomas in HIV-seropositive patients. Frequency, features, and prognosis. Report on 31 cases.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Central Nervous System Neoplasms; | 1991 |
Effects of prednisone on human immunodeficiency virus infection.
Topics: Adolescent; Child; Drug Administration Schedule; Drug Evaluation; Follow-Up Studies; Hemophilia A; H | 1991 |
Human immunodeficiency virus wasting syndrome may represent a treatable myopathy.
Topics: Acquired Immunodeficiency Syndrome; Adult; HIV Infections; HIV Seropositivity; Humans; Middle Aged; | 1990 |
Thrombocytopenic purpura in HIV-seronegative users of intravenous cocaine.
Topics: Cocaine; HIV Seropositivity; Humans; Injections, Intravenous; Platelet Count; Prednisone; Purpura, T | 1990 |
Immunologic thrombocytopenic purpura and human immunodeficiency virus (HIV) in a married heterosexual couple.
Topics: Adult; Family Health; Female; gamma-Globulins; HIV Seropositivity; Humans; Male; Prednisone; Sex Wor | 1989 |
Serologic and immunologic correlates of retroviral infection in transplant recipients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Azathioprine; Cyclosporins; Drug Therapy, Combination; Fe | 1989 |
Fulminant Kaposi's sarcoma complicating long-term corticosteroid therapy.
Topics: Adult; Crohn Disease; Cytomegalovirus Infections; Familial Mediterranean Fever; Female; HIV Seroposi | 1987 |
Splenectomy for immune thrombocytopenia related to human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Deltaretrovirus Infections; Follow-Up Studies; HIV Seropositivit | 1988 |
Unusual manifestations of secondary syphilis and abnormal humoral immune response to Treponema pallidum antigens in a homosexual man with asymptomatic human immunodeficiency virus infection.
Topics: Adult; Antibodies, Bacterial; Arthritis, Reactive; Chorioretinitis; Drug Therapy, Combination; HIV S | 1988 |
Atypical presentation of Hodgkin's disease in a patient at risk for the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophos | 1988 |